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Exposure to Ceftobiprole Is Associated with Microbiological
Eradication and Clinical Cure in Patients with Nosocomial Pneumonia
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Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlandsa; Department of Medical Microbiology, St. Elisabeth Hospital, Tilburg, The Netherlandsb;
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The percentage of the dosing interval that the non-protein-bound plasma concentration is above theMIC (%fT>MIC) for ceph-
alosporins has been shown to correlate with microbiological outcomes in preclinical studies. However, clinical data are scarce.
Using data from a randomized double-blind phase 3 clinical trial, we explored the relationship of ceftobiprole exposure with
microbiological and clinical outcomes in patients with nosocomial pneumonia. The individual ceftobiprole exposure was deter-
mined for different pharmacokinetic (PK)/pharmacodynamic (PD) indices using individual pharmacokinetic data and a previ-
ously published populationmodel. TheMICs used in the analysis were the highest MICs for any bacterium cultured at baseline
or the end of treatment (EOT). Outcomes were microbiological cure at EOT and clinical cure at test of cure (TOC). Multiple lo-
gistic regression (MLR) and classification and regression tree (CART) analyses were applied to determine the relationships
among exposure, patient characteristics, and outcomes. MLR indicated that the %fT>MIC of ceftobiprole was the best predictor
for both microbiological eradication and clinical cure. CART analysis showed a breakpoint value of 51.1% (n 159; P 0.0024)
for clinical cure, whereas it was 62.2% (n 251; P< 0.0001) for microbiological eradication. Other factors also contributed, par-
ticularly to clinical outcome. These included the difference between VAP and non-VAP patients, systemic inflammatory re-
sponse syndrome (SIRS), creatinine clearance, the use of anti-Pseudomonas combination therapy, and Acute Physiology and
Chronic Health Evaluation II (APACHE-II) score. There is a strong correlation betweenmicrobiological eradication and clinical
cure with exposure to ceftobiprole. The %fT>MIC required to result in a favorable clinical outcome is>51% of the dosing inter-
val, which is in line with the values found for microbiological eradication, the comparator ceftazidime, and preclinical models.
Ceftobiprole, the active moiety of its prodrug ceftobiprole me-docaril, is a broad-spectrum cephalosporin active against
most Gram-positivemicroorganisms, includingmethicillin-resis-
tant Staphylococcus aureus (MRSA), as well as Gram-negative mi-
croorganisms. Similar to other -lactams, studies in animals and
in vitro pharmacokinetic (PK) models have shown that the per-
centage of the dosing interval that themaximum concentration of
the free, unbound fraction of drug in serum is above the MIC
(%fTMIC) is the PK/pharmacodynamic (PD) index that best
correlates with drug-related response (1). A %fTMIC of 60 to
65% of the dosing interval has been identified in mouse infection
models as the target of near-maximal bacterial killing, and a
%fTMIC of 40% best predicted bacteriostasis at 24 h for ceph-
alosporins in general (2–4). These %fTMIC values are often
regarded as PD targets for drug exposure and as the values on
which to base clinical breakpoints, and in general as targets to
reach during therapy (5).Whereas data to support the use of these
targets in clinical infections in humans for quinolones and glyco-
peptides have appeared over the last decade (6–8), the clinical
evidence for beta-lactams was limited until recently, when a cor-
relation between exposure to ceftazidime and microbiological
eradication as well as clinical cure was demonstrated in patients
with nosocomial pneumonia. Patients in whom a%fTMIC of at
least 44.9%was reached had a higher probability of bacterial erad-
ication than patients with a lower exposure (9), and a significant
relationship between %fTMIC and clinical cure was also dem-
onstrated. In addition, in a trial comparing continuous infusion
versus intermittent infusion, Dulhunty et al. (10) demonstrated
that the former was superior. In the present study, we investigated
the relationships between microbiological eradication as well as
clinical cure and exposure to ceftobiprole, using the data gener-
ated in a large phase 3 clinical trial.
MATERIALS AND METHODS
Trial, data set, and treatment.Thiswas a post hoc analysis of a clinical trial
conducted between 2005 and 2007 to compare the efficacy of ceftobiprole
to that of a combination of ceftazidime and linezolid for treatment of
nosocomial pneumonia (NP), including ventilator-associated pneumo-
nia (VAP). It was a randomized, double-blind, multicenter global phase 3
study involving 781 subjects (trial database, NCT00210964), of which all
data recorded in the trial database were provided to the authors. The
methodology of the trial is described elsewhere (9). The sample size of the
original study was based on a noninferiority design with a margin of 15%
and a power of 90%, with a total number of 770 subjects needed for
randomization into both arms of the study. Included subjects were ran-
domly assigned to treatment centrally in a 1:1 ratio to ceftobiprole (500
mg every 8 h, 2-h intravenous [i.v.] infusion) or linezolid (600mg every 12
h, 1-h i.v. infusion) plus ceftazidime (2 g every 8 h, 2-h i.v. infusion) for 7
to 14 days. Subjects were stratified by infection type (non-ventilator-as-
sociated pneumonia [VAP] and VAP) and by Acute Physiology and
Chronic Health Evaluation II (APACHE II) scores (scores of 8 to 19 and
20 to 25, respectively). Subjects who had VAP were further stratified by
time to randomization after onset of mechanical ventilation (5 or 5
days of ventilation). An independent data-monitoring committee was
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established to monitor data on an ongoing basis. Combination therapy
(levofloxacin, amikacin, or gentamicin) was permitted in subjects at risk
for pseudomonal infections. Subjects were evaluated before the start of
therapy (baseline [BL]), during therapy, and at the end of therapy (EOT)
within 24 h after the last administration of the study drug. A test-of-cure
(TOC) evaluation was performed 7 to 14 days after the EOT visit.
None of the patients were excluded from the current analysis.
Microbiology.Cultureswere taken at BL, at EOT, and if possible at the
TOC visit. Microbiological procedures were conducted according to local
practice. Duplicate isolates from all assessments were stored and shipped
to the central laboratory (Eurofins, Inc., Chantilly, VA) for pathogen
identification and antimicrobial susceptibility testing using broth mi-
crodilution (11). Suitable specimens for ventilated subjects included those
obtained by bronchoscopy with bronchoalveolar lavage/protected-brush
sampling or transtracheal/endotracheal aspiration and for nonventilated
patients included those obtained by deep expectoration or nasotracheal
aspiration. Subsequently, the samples were processed according to local
practices. Subjects with insufficient or unsuitable sputum specimens
should have had the specimen repeated within 24 h of randomization.
MICs determined in the central laboratory were used in the present anal-
yses.
Calculation of individual PK parameter estimates and PK/PD indi-
ces. A nonlinear mixed-effects modeling (NONMEM) population phar-
macokinetic model as previously described was used (12). Briefly, data
were best described by a 3-compartment model and included two covari-
ates, creatinine clearance on clearance and age on the central volume of
distribution. For patients with at least one serum sample, individual PK
parameters were estimated by NONMEM as post hoc Bayesian estimates
(n 52). For patients without individual NONMEM estimates, parame-
ter values were estimated using covariates (n 312) as determined in the
population PKmodel based on 171 individuals. Subsequently, the PK/PD
indices %fTMIC, area under the concentration-time curve for the free,
unbound fraction of a drug (fAUC), fAUC/MIC, maximum concentra-
tion of the free, unbound fraction of drug in serum (fCmax), and fCmax/
MIC were calculated for each individual patient using the KinFun106
program (Medimatics, Maastricht, the Netherlands). KinFun is based on
an equation solver built in Excel using standard 2- and 3-compartment
pharmacokinetic models and was used to calculate measures of exposure
(%fTMIC and fAUC/MIC) using estimates for the PK parameters, pro-
tein binding, and MICs. Steady state was assumed for calculations. A
protein binding of 16% was used (13).
The indices were determined based on MICs in two different ways.
The first was by taking the highest MIC of any pathogen cultured at BL.
The second was by taking the microorganism with the highest MIC value
at either BL or EOT (BL/EOT). Both Gram-negative and Gram-positive
bacteria were included in the analysis.
Treatment outcome. Various measures of outcome were used. At
EOT the microbiological outcome was defined in two different ways. The
first measure was eradication at EOT of the microorganism(s) cultured at
baseline (outcome-BL-microorganism). For the second measure, if any
microorganism was cultured at EOT, treatment was considered to have
failed and was therefore independent of a positive or negative culture at
baseline (outcome-EOT-culture). The analysis was performed for all pa-
tients in the intent-to-treat population (ITT) with a positive culture and
for which the PK/PD indices could be derived. They represent the ITT
PK/PD subset. At the TOC visit, both microbiological eradication and
clinical outcome as well as clinically evaluable (CE) andmicrobiologically
evaluable (ME) designations were used as defined per protocol and as
described previously (9).
Statistical analysis. PK/PD indices were correlated withmicrobiolog-
ical outcome at EOT. For correlations of exposureswith outcomes at TOC
visit, theME populationwas studied formicrobiological outcome and the
CE population for clinical outcome.
CART analysis to differentiate between lower and higher response
rates and (multiple) logistic regression were performed using SAS (JMP)
software version 9.02 and SAS 9.2 (SAS Institute, Cary, NC). Tests of
significance for CART analysis were performed using Fisher’s test (2
sided) as implemented in GraphPad Prism version 5.0 (GraphPad Soft-
ware, Inc., San Diego, CA). For the multiple logistic regression, data for
%fTMIC, fAUC/MIC, fCmax/MIC, volume of distribution at steady
state, APACHE II score, age, sex, body weight, body mass index, height,
albumin, white-blood-cell count, creatinine clearance, creatinine, C-re-
active protein (CRP), systemic inflammatory response syndrome (SIRS),
and combination therapy with an antipseudomonal antibiotic and infec-
tion type (non-VAP/VAP) were entered in the model with entry levels of
0.25 and stay of 0.1, and subsequently both forward and backward selec-
tions were performed.
RESULTS
Patient population and demographics. The total NP trial data-
base consisted of 391 patients treated with ceftobiprole. There
were 257 patients with a positive culture at BL and 267 at BL/EOT.
For 27 patients, pharmacokinetic data were not available or could
not be estimated because creatinine clearance was not available.
Thus, PK/PD indices were calculated based on BL cultures for 243
individuals and based on BL/EOT cultures for 251 individuals.
The demographic data of these patients are shown in Table 1.
Microbiology. Of the 257 patients with positive culture at
baseline, 177 patients had a positive culture with at least one
Gram-negative microorganism and 130 with at least one Gram-
positivemicroorganism.Of the 267 patients with positive cultures
at BL/EOT, 189 patients had at least one Gram-negative microor-
ganism and 133 patients had at least one Gram-positive microor-
ganism in the cultures, respectively. In most patients with a posi-
tive culture, 1 or 2microorganisms were identified, but with up to
7 different microorganisms per patient (Table 2).
Exposure-response (PK/PD) analysis at end of treatment:
microbiological outcome. Multiple logistic regression (MLR)
analysis using stepwise selection was performed to determine fac-
tors contributing to explaining exposure-response relationships.
For eradication of BL microorganisms at EOT, the most signifi-
cant factor entered in the model was %fTMIC (P  0.0003).
However, creatinine clearance was also significant (P  0.0039)
TABLE 1 Demographic data of patients with a positive culture in the
NP trial database
Parameter
Valuesa for patients used in analysis with:
PK/PD indices
(n 251)
Positive culture at
BL/EOT (n 267)
Age (yr) 60.3 (19–92) (251) 59.7 (19–92) (267)
Sex (no. male/no. female) 180/71 189/78
Weight (kg) 73.3 (29–129) (251) 73.1 (29–129) (265)
BMIb (kg/m2) 25.5 (11.3–42.9) (245) 25.4 (11.3–42.9) (259)
Creatinine clearance
(ml/min)
106 (17.0–475) (250) 106 (17.0–475) (250)
Infection type
(VAPc/non-VAP)
69/182 79/188
SIRS (no. yes/no. no) 189/62 197/70
APACHE II score 14.0 (8–26) (251) 14.1 (8–26) (267)
Anti-Pseudomonas
combination therapy
(no. yes/no. no)
47/204 51/216
a Values for all parameters except sex, infection type, and anti-Pseudomonas
combination therapy are given as the mean (range) (number of patients).
b BMI, body mass index.
c VAP, ventilator-associated pneumonia.
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(Table 3). Since the trial was stratified for non-VAP or VAP, a
separate MLR analysis in each of the subgroups was performed.
For non-VAP patients, %fTMIC was the most significant vari-
able entered in the model (P 0.0033), but the MIC by itself was
also significant (P  0.0321). For VAP patients there were no
significant predictors.
For microorganisms cultured at BL/EOT, %fTMIC was the
most significant predictor (P 0.0001) using MLR, but SIRS was
also marginally significant (P  0.0472) (Table 3). In the sub-
group analysis,%fTMICwas themost significant predictor (P
0.0001) in the non-VAP subgroup but SIRS was also marginally
significant (P  0.0476). In the VAP subgroup, %fTMIC was
the only significant predictor (P 0.0013). Subsequent univariate
analyses showed significant correlations between %fTMIC and
microbiological eradication at EOT (Fig. 1A and B). The Hosmer
and Lemeshow goodness-of-fit test was nonsignificant, indicating
a good fit.
To determine the optimal split value for microbiological out-
come for each potential predictor, aCARTanalysis was performed
(Table 4). Both the highest MIC value of the microorganism cul-
tured at BL and the highestMICvalue ofmicroorganisms cultured
at BL/EOT were significantly correlated with microbiological
eradication at EOT.All three PK/PD indiceswere also significantly
associated withmicrobiological eradication at EOT. A%fTMIC
of at least 51.1% was correlated with microbiological eradication
at EOT for patients in both the non-VAP subgroup and the VAP
subgroup (P 0.0001 and P 0.0004, respectively).
Exposure-response (PK/PD) analysis at test of cure clinical
outcome. To determine the most important predictor(s) of clin-
ical cure, MLR was performed. Using the BLMIC values to calcu-
late the exposure, the most significant predictor was non-VAP
versus VAP patient (P  0.0001). Other significant independent
predictors were SIRS (P  0.0049), anti-Pseudomonas combina-
tion therapy (P 0.0177), and%fTMIC (P 0.0445) (Table 5).
Because the difference between non-VAP and VAP patients was
themost significant predictor and a stratification factor during the
trial, a separate MLR analysis was performed for each of the two
subgroups. In the non-VAP subgroup, SIRS (P  0.0025), anti-
Pseudomonas combination therapy (P 0.0324), and %fTMIC
(P  0.0401) were independent significant predictors of clinical
cure at TOC, whereas there was no significant predictor in the
VAP subgroup.
When the exposure to ceftobiprole was based on BL/EOT
MICs,MLR showed significance for non-VAP patient versus VAP
patient (P  0.0001), %fTMIC (P  0.0062), and APACHE II
score (P  0.0376) (Table 5). A separate subgroup analysis for
VAP and non-VAP revealed a single predictor for clinical cure at
TOC, %fTMIC (P  0.0023, n  130), in the non-VAP sub-
group. The APACHE II score was not significant in this subgroup.
Within the VAP subgroup there were no significant predictors
(n 36).
Univariate logistic regression of %fTMIC for the total pop-
ulation showed that the relationship with clinical cure was not
quite significant (P 0.0537) (Fig. 2A) if based on BL, whereas it
was highly significant for BL/EOT microorganism (P  0.0088)
(Fig. 2B). For both analyses, the Hosmer and Lemeshow test was
not significant, indicating no lack of fit. Subgroup analysis within
the non-VAP subgroup showed significant relationships for BL as
well as BL/EOT (P 0.0144 and P 0.0023, respectively).Within
the VAP subgroups, these relationships were nonsignificant. This
analysis was further substantiated by the CART analysis (Table 6)
showing that clinical cure was not significantly associated with the
MIC of the BL microorganism, but was significantly correlated
with the MIC of the BL/EOT cultures. Significant relationships
were demonstrated between exposure based on BL and BL/EOT
MICs. The %fTMIC was the index best correlated with clinical
cure, with a split value of 51.1%fTMIC, P is 0.0243 for BL and P
is 0.0029 for BL/EOT, respectively.
TABLE 2 Species cultured at BL and BL/EOT
Species with the highest
MICs
BL cultures (n 257
positive cultures)
BL/EOT cultures (n
267 positive cultures)
No. of
the
highest
MICs
Range of
highest
ceftobiprole
MICs
(mg/liter)a
No. of
the
highest
MICs
Range of
highest
ceftobiprole
MICs
(mg/liter)a
Gram-negative bacteria
Acinetobacter spp. 20 0.12–32 29 0.12–32
Citrobacter spp. 4 0.06–8 4 0.06–8
Enterobacter spp. 18 0.03–32 15 0.03–32
Escherichia coli 32 0.03–32 33 0.03–32
Haemophilus influenzae 5 0.008–0.12 5 0.008–0.12
Klebsiella spp. 32 0.03–32 37 0.03–32
Pseudomonas spp. 45 0.25–32 46 0.5–32
Proteus spp. 6 0.015–32 6 0.03–32
Serratia spp. 8 0.12–32 7 0.12–32
Stenotrophomonas
maltophilia
7 32 10 32
Miscellaneous spp. 12 0.008–32 13 0.008–32
Gram-positive bacteria
Corynebacterium spp. 2 0.12b 2 0.12b
Enterococcus spp. 5 0.25–32 5 0.25–32
Staphylococcus aureus 97 0.12–8 100 0.12–8
Staphylococcus spp.
(excluding S. aureus)
12 0.12–4 12 0.12–4
Streptococcus
pneumoniae
9 0.008–1 9 0.008–1
Streptococcus spp.
(excluding S.
pneumoniae)
7 0.002–1 7 0.03–1
a MICs of16 mg/liter were recorded as 32 mg/liter.
b In one strain, the MIC was not determined.
TABLE 3Multiple logistic regression analysis of factors determining
microbiological eradication of BL and BL/EOT microorganisms at EOT
Culture time (n) and
covariate Coefficient SE Chi square P
BL (242)
Intercept 1.5395 0.4271 12.9934 0.0003
%fTMIC 0.0145 0.00403 12.9630 0.0003
Creatinine clearance 0.00726 0.00251 8.3395 0.0039
BL/EOT (251)
Intercept 0.8538 0.3738 5.2163 0.0224
%fTMIC 0.0253 0.00363 48.5401 0.0001
SIRS 0.7497 0.3778 3.9370 0.0472
Muller et al.
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DISCUSSION
Analysis of a phase 3 study in patients with nosocomial pneumo-
nia showed thatmicrobiological outcome at EOT and clinical out-
come at TOC in patients treated with ceftobiprole were signifi-
cantly correlated with exposure to this drug. %fTMIC was the
PK/PD index correlated with the highest probability of microbio-
logical and clinical cure. A high probability of clinical cure at TOC
was attained at values of51.1% fTMIC, whereas for microbi-
ological cure slightly higher values were required to achieve the
highest probability of microbiological eradication at EOT (62.2%
fTMIC for BL/EOT cultures). Whereas for microbiological
eradication at EOT only%fTMICwas a significant predictor for
success outcome, other patient-related factors significantly con-
tributed to clinical cure at TOC as well. These results compare
well with the PK/PD analyses of ceftazidime and Gram-negative
microorganisms in the comparator arm of the trial, where
%fTMIC was also identified as the parameter correlating with
outcome in patients (9).
To calculate the PK/PD indices, we used the highest MIC en-
countered, reasoning that outcome would be related to the bacte-
riawith the lowest exposure in casemultiplemicroorganismswere
cultured (9, 14). The cultures that were used were taken at BL and
at EOT. We did not take TOC cultures into account. There is a
significant time lapse between EOT and TOC, with significant
recolonization or disappearance of the microorganism that can-
not be attributed directly to therapy. These are very likely inter-
fering with the actual effect of exposure during and immediately
after treatment. However, changes in microbiology or MICs dur-
FIG 1 Univariate logistic regression analysis of %fTMIC for microbiological eradication at EOT for the exposure based on BLMICs (A) (n 243) and based
on BL/EOTMICs (B) (n 251) for all patients. (A) P 0.0002. The gray area represents the 95% prediction interval. (B) P 0.0001. The gray area represents
the 95% prediction interval.
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ing therapy can be considered a direct effect of treatment. We
therefore used two different data sets to determine the highest
MIC of culturedmicroorganisms, one at BL and the other includ-
ing MICs of microorganisms at the end of therapy. Likewise, we
defined two different microbiological outcome measures. In the
first outcome measure we took the conventional approach and
determined whether microorganisms cultured at BL were eradi-
cated at EOT. In addition, we defined the second outcome mea-
sure from combined BL and EOT cultures. Both approaches re-
sulted in %fTMIC as the only significant PK/PD index
predictive for a favorable outcome, but the BL/EOT approach was
more significant. This is predictable, as most likely patients be-
come colonized before or during therapy with microorganisms
that have relatively high MICs. The results indicate that these pa-
tients have a higher probability of microbiological as well as clin-
ical failure.
The exposure curve of %fTMIC as a function of the MIC is
relatively steep. Because of the relatively long duration of infusion
(2 h) and half-life (approximately 3 h) of ceftobiprole, the con-
centration time curve is relatively flat. The consequence hereof is
that concentrations are either above theMICor below theMIC for
the full duration of the dosing interval for themajority of patients,
corresponding to %fTMIC values of 100 and 0, respectively.
This is coming close to what is observed for patients receiving
continuous infusion. A similar distribution of %fTMIC versus
MICwas observed for ceftazidime infused over 2 h in the compar-
ator armof the trial (9). This phenomenon is especially the case for
the outcome measure based on BL cultures only, because of the
relatively high number of microorganisms with low MICs. As a
result, the split values as determined by CART analysis can be
influenced by relatively small changes in the numbers. For exam-
ple, microbiological eradication of BL microorganisms at EOT is
significantly associated with exposure to ceftobiprole, with a split
value of 100% fTMIC, but there is also a second split value of
51% fTMIC, which is also significant and concurs with values
described elsewhere, i.e., 45% fTMIC for ceftazidime and
Gram-negative microorganisms in the comparator arm (9, 15).
Similar to the exposure-response relationship found for other
antimicrobials (6, 7, 16, 17), the relationship found here indicates
that optimal exposure increases the likelihood of microbiological
eradication. In patients with insufficient exposure to ceftobiprole,
the probability of microbiological eradication is approximately
44%, whereas the probability of microbiological eradication in
patients with an exposure of 100% is 91%. Therefore, one might
conclude that the additional effect of optimal treatment with
ceftobiprole is approximately 47%. A similar observation was
madewith ceftazidime, for which at very low exposure (up to 25%
TABLE 4 Results of CART analysis for microbiological eradication (outcome) at EOT for a BL and BL/EOT microorganism
Outcome and predictor
Split
value
Successa in group
with value more
than the split
value (no.)
Failureb in group
with value more
than the split
value (no.)
Successa in group with
value less than or
equal to the split
value (no.)
Failureb in group with
value less than or
equal to the split
value (no.) Pc
Microbiological eradication at EOT
of BL microorganismd (243
patients)
MICe 2 69 27 136 11 0.0001
%fTMIC 100 157 14 48 24 0.0001
%fTMICf 51.2 168 37 19 19 0.0001
fAUC/MIC 197.8 103 4 102 34 0.0001
fCmax/MIC 9.31 150 12 55 26 0.0001
Microbiological eradication at EOTg
(251 patients)
MICe 8 47 46 143 15 0.0001
%fTMIC 62.2 154 16 36 45 0.0001
fAUC/MIC 12.1 154 16 36 45 0.0001
fCmax/MIC 2.22 155 16 35 45 0.0001
a Failure instead of success for MIC.
b Success instead of failure for MIC.
c The P value refers to the significance of the split value.
d Outcome: eradication at end of treatment of the microorganisms cultured at baseline.
e In 2-fold dilution series.
f Alternative split.
g Outcome: positive or negative culture at end of treatment.
TABLE 5Multiple logistic regression analysis of factors determining
clinical cure at TOC for all patients
Culture time (n) and
covariate Coefficient SE Chi square P
BL (159)
Intercept 0.3157 0.5505 0.3289 0.5663
NP vs VAP patient 1.9829 0.4611 18.4919 0.0001
SIRS 1.2103 0.4300 7.9238 0.0049
Anti-Pseudomonas
combination
therapy
1.1350 0.4785 5.6256 0.0177
%fTMIC 0.0103 0.00514 4.0376 0.0445
BL/EOT (166)
Intercept 1.5638 0.6930 5.0926 0.0240
NP vs VAP patient 2.0851 0.4464 21.8203 0.0001
%fTMIC 0.0118 0.00431 7.4787 0.0062
APACHE score 0.0892 0.0429 4.3208 0.0376
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fTMIC) almost half the patient population is microbiologically
cured (9). For both compounds, factors contributing to this effect
include the use of other antibiotics, the immune systems of the
patients, and the state of the disease. This has similarly been de-
scribed for other antibiotics (3).
Similar to our results in humans, a thigh infection model in
neutropenic mice showed that the PK/PD index best correlated
with effect is %fTMIC. The %fTMIC required for a static ef-
fect varied between 14% and 48% of the dosing interval (15). In
these experiments, the %fTMIC required was twice as long for
Enterobacteriaceae as for Staphylococcus aureus or Streptococcus
pneumoniae (15). A higher percentage of time above the MIC
required for ceftobiprole against Enterobacteriaceae than required
against S. aureus and S. pneumoniae was also reported in other
studies (18–20). These studies also showed no differences in effi-
cacy between the thigh model and the lung model. The values
found in this study, in which a%fTMIC values of 51 to 62% and
51% were required for microbiological or clinical response, re-
spectively, also concur with those found for ceftazidime, where a
%fTMIC of 45% of the dosing interval for the eradication of
Gram-negative microorganisms has been described earlier in pa-
tients with nosocomial pneumonia (9).
The split values found for microbiological eradication and
clinical cure were comparable. However, multiple logistic regres-
sion analysis indicated that VAP status by itself was the most im-
portant predictor for clinical cure, even with %fTMIC as a sig-
FIG 2 Univariate logistic regression analysis of %fTMIC and clinical cure at TOC for exposures based on BLMICs (A) (n 159) and based on BL/EOTMICs
(B) (n 166) for the total population. (A) P 0.0537. The gray area represents the 95% prediction interval. (B) P 0.0088. The gray area represents the 95%
prediction interval.
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nificant predictor in the univariate analysis. Although within the
non-VAP subgroup%fTMIC was an independent predictor for
clinical cure, it was not in the VAP subgroup. This could not be
explained by differences in pharmacokinetics between the two
subgroups, as we did not find differences in exposure. The split
value formicrobiological eradication of 51.1%was similar in both
the VAP and non-VAP -subgroups, and the proportions of pa-
tients above and below the split value were not significantly dif-
ferent in the non-VAP and VAP subgroups (68% versus 70%).
Since we determined the correlation between the exposure of
the comparator ceftazidime and clinical outcomes for patients
infected with Gram-negative bacteria in an earlier analysis (9), we
explored whether significant differences between ceftazidime and
ceftobiprole exposures could explain the difference in outcome in
the VAP subgroup. In the ceftobiprole arm, 34 patients had expo-
sures higher than the split value and 19 had exposures below this
value, whereas in the ceftazidime arm these numbers were 26 and
23, respectively, indicating similar exposures in theVAP subgroup
between patients treated with ceftobiprole or with ceftazidime
(Fisher’s exact test,P 0.315). There appears to be no explanation
within the PK/PD analysis for the difference between the two sub-
groups.
We conclude that there is a strong correlation between micro-
biological eradication as well as clinical cure with exposure to
ceftobiprole. The %fTMIC that is required to result in likely
favorable clinical outcome is51%,which is in linewith the value
found for microbiological eradication and values found in pre-
clinical models.
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